Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 1,420,000 shares, a drop of 21.5% from the November 30th total of 1,810,000 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average trading volume of 4,630,000 shares, the days-to-cover ratio is presently 0.3 days.

Analysts Set New Price Targets

ATHA has been the topic of several recent research reports. Rodman & Renshaw cut shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th. BTIG Research lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. JMP Securities cut shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 4th. Finally, Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $5.00 to $0.50 in a research report on Thursday, September 19th.

Athira Pharma Stock Performance

Athira Pharma stock opened at $0.55 on Friday. Athira Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $4.30. The firm has a 50 day moving average price of $0.60 and a 200 day moving average price of $1.58. The company has a market capitalization of $21.26 million, a PE ratio of -0.19 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. As a group, equities research analysts forecast that Athira Pharma will post -2.35 earnings per share for the current year.

Institutional Trading of Athira Pharma

A number of large investors have recently modified their holdings of the stock. Rothschild Investment LLC purchased a new position in Athira Pharma in the second quarter worth approximately $34,000. XTX Topco Ltd purchased a new stake in shares of Athira Pharma during the 2nd quarter worth approximately $60,000. Invst LLC acquired a new stake in Athira Pharma during the 2nd quarter worth $68,000. American Century Companies Inc. boosted its stake in Athira Pharma by 9.4% in the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after acquiring an additional 3,333 shares in the last quarter. Finally, Forefront Analytics LLC increased its position in shares of Athira Pharma by 126.0% during the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after purchasing an additional 25,979 shares in the last quarter. Hedge funds and other institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.